March 25, 2020, 09:00 AM EDT
Title: “Lilly Monoclonal Antibody Pharmacokinetics: Clinical Comparisons and Non-clinical to Clinical Predictions”
Speakers: Dr. Patricia Brown-Augsburger, Ph.D. and Dr. Bryan Jones, Ph.D.
A cross-functional team is conducting a comparison of the pharmacokinetic characteristics of Lilly portfolio antibodies with external approved antibodies. Comparisons demonstrated poorer mean clearance, which improved over time with implementation of biophysical screening tools. Bioavailability of the Lilly portfolio antibodies is lower than the external dataset, and thus optimization of this parameter presents an important opportunity for improvement. The team is exploring the hypothesis that biochemical / biophysical properties are at the heart of these differences. Initial, computational approaches have led to the identification of properties that help describe biochemical differences associated with molecule pharmacokinetics. Additional generation of experimental biophysical data and non-clinical pharmacokinetic data are planned, with the objective of optimizing antibody selection in the future.